XFOR
X4 Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$389.14M
P/E Ratio
—
EPS
$-1.87
Beta
0.33
52W High
$6.63
52W Low
$1.35
50-Day MA
$3.86
200-Day MA
$3.42
Dividend Yield
—
Profit Margin
-225.60%
Forward P/E
—
PEG Ratio
—
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back diseases. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $35.11M |
| Gross Profit (TTM) | $29.36M |
| EBITDA | $-78.61M |
| Operating Margin | -931.00% |
| Return on Equity | -76.00% |
| Return on Assets | -22.90% |
| Revenue/Share (TTM) | $0.83 |
| Book Value | $2.05 |
| Price-to-Book | 2.16 |
| Price-to-Sales (TTM) | 11.08 |
| EV/Revenue | 6.44 |
| EV/EBITDA | 1.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 79.10% |
| Shares Outstanding | $90.92M |
| Float | $64.55M |
| % Insiders | 0.63% |
| % Institutions | 90.29% |
Historical Volatility
HV 10-Day
51.17%
HV 20-Day
70.25%
HV 30-Day
92.06%
HV 60-Day
86.54%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($11.67 target)
3
BuyData last updated: 4/24/2026